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Background/Aims
Since the use of dexlansoprazole in Asian subjects with gastroesophageal reflux disease (GERD) has not been adequately characterized, 
this study was conducted to evaluate the efficacy and safety of dexlansoprazole modified-release in Asian subjects with non-erosive 
reflux disease (NERD) and erosive esophagitis (EE).
Methods
In this phase 4, open-label, non-randomized, uncontrolled, multicenter, multi-country study sponsored by Takeda, subjects aged ≥ 20 
years with persistent typical GERD symptoms for at least 6 months underwent endoscopy. Based on endoscopic findings, they were 
assigned to either dexlansoprazole modified-release 30 mg once-daily for 4 weeks (NERD group) or dexlansoprazole modified-release 
60 mg once-daily for 8 weeks (EE group). The primary endpoint was the percentage of days that subjects did not experience any 24-
hour heartburn or acid regurgitation.
Results
Of the 445 subjects screened from Hong Kong, South Korea, and Taiwan, 208 were enrolled in the NERD group (mean age: 53.6 
years, male: 34.6%) and 88 in the EE group (mean age: 51.7 years, male: 55.7%). Over the treatment period, the median percentage 
of days that subjects did not experience any 24-hour heartburn or acid regurgitation was 26.9% and 65.5% in the NERD and EE 
groups, respectively; for nighttime heartburn or acid regurgitation the proportions were 59.3% and 83.3%, respectively. The treatment 
was well tolerated with low incidence of treatment-related adverse events in NERD and EE groups (6.7% and 5.7%, respectively).
Conclusion
In Asian patients with GERD, treatment with dexlansoprazole modified-release indicates a favorable efficacy and safety profile in 
relieving heartburn and acid regurgitation symptoms.
(J Neurogastroenterol Motil 2020;26:85-95)
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Introduction  
Gastroesophageal reflux disease (GERD) is defined as a con-
dition that develops when the reflux of stomach contents causes 
troublesome symptoms and/or complications. Non-erosive reflux 
disease (NERD) is defined by the presence of troublesome reflux-
associated symptoms and the absence of mucosal breaks in the 
esophagus at endoscopy; when erosions are present, it is called 
erosive esophagitis (EE).1 GERD is a common condition. A recent 
meta-analysis reported a prevalence of 18.1-27.8% in North Amer-
ica, 8.8-25.9% in Europe, 2.5-7.8% in East Asia, 8.7-33.1% in the 
Middle East, 11.6% in Australia, and 23.0% in South America. 
The prevalence of GERD appears to be increasing, especially in 
Asia, where the rates are beginning to approach those reported in 
Western countries.2-4
Patients generally consider mild symptoms occurring 2 or 
more days a week, or moderate/severe symptoms occurring more 
than 1 day a week to be troublesome.1 Frequent or severe GERD 
symptoms are associated with impaired quality of life and activities 
of daily living.5,6 These symptoms also result in decreased work pro-
ductivity and increased costs.7 GERD is also commonly associated 
with nocturnal symptoms and sleep disturbances, which further 
contribute to disease burden.1,8,9
Proton pump inhibitors (PPIs) are the mainstay in the manage-
ment of GERD.10 However, a sizeable proportion of patients con-
tinue to experience persistent GERD symptoms despite treatment 
with the current PPIs. In a systematic review of the literature, the 
prevalence of persistent heartburn despite PPI treatment was 17% 
in interventional non-randomized studies and 32% in randomized 
trials.11 The prevalence of persistent GERD symptoms despite 
treatment was 45% in observational studies.11 This persistence 
of symptoms results in increased burden, with patients reporting 
impaired sleep, impaired quality of life, reduced productivity, and 
increased cost of illness despite PPI treatment.10,12-14
Dexlansoprazole is a PPI that constitutes > 80% of circulat-
ing drug after oral administration of the PPI lansoprazole, and is 
more stable than lansoprazole. Dexlansoprazole modified-release is 
a novel modified-release formulation of dexlansoprazole, in which 
a dual delayed-release technology is used for extended duration of 
acid suppression. In this technology, 2 types of granules are used 
to ensure initial release of the drug in the proximal small intestine 
followed by a delayed release many hours later, in the distal small 
intestine.15 The safety and efficacy of dexlansoprazole has been 
demonstrated for the treatment of symptomatic GERD or NERD 
and safe and prolonged healing of EE, and it is approved for use in 
many countries across the world.15,16
The registration studies for dexlansoprazole mostly involved 
doses of 60 mg/day and 90 mg/day. In Asian subjects with GERD, 
the use of dexlansoprazole has not been adequately characterized 
at the dose regimens of 30 mg/day for NERD and 60 mg/day for 
EE. This phase 4 study was conducted to evaluate the efficacy and 
safety of the use of dexlansoprazole delayed-release in Asian sub-
jects with GERD who manifest endoscopic evidence of NERD 
and EE.
Materials and Methods  
This was a phase 4, open-label, non-randomized, uncontrolled, 
multicenter, multi-country study. Subjects were enrolled at 12 in-
vestigational sites in Asia, including 1 site in Hong Kong, 6 sites in 
South Korea, and 5 sites in Taiwan. Study sites mostly consisted of 
referral centers with expertise in GERD and with adequate facilities 
to perform study-related activities including endoscopy. The study 
was conducted from March 2015 to July 2016.
Key Eligibility Criteria
Male or female subjects aged ≥ 20 years were eligible for the 
study if they had experienced persistent typical GERD symptoms 
(heartburn and/or acid regurgitation) for at least 6 months with the 
presence of GERD symptoms for at least 4 days within the past 7 
days prior to the screening visit. Throughout the screening period 
the subjects documented the presence and maximum severity of 
daytime and nighttime heartburn and acid regurgitation symptoms 
each day in a paper diary. In addition, subjects were assessed for 
heartburn, acid regurgitation, dysphagia, belching, and epigastric 
pain as recorded by the investigator (clinician). During screening 
endoscopy, the subjects either needed to have macroscopically nor-
mal esophageal mucosa (NERD group) or have evidence of erosive 
esophageal reflux disease, Los Angeles (LA) classification grades B 
to D (EE group).
Key exclusion criteria related to the gastrointestinal system were 
as follows: known hypersensitivities to any PPI and component of 
dexlansoprazole; use of a histamine H2 blocker or a PPI other than 
dexlansoprazole during screening and throughout the study; previ-
ous use of dexlansoprazole before screening; endoscopic Barrett’s 
esophagus and/or definite dysplastic changes in the esophagus; 
active gastric or duodenal ulcers within 4 weeks of the first dose of 
study drug; history of dilation of esophageal strictures other than a 
Schatzki’s ring; coexisting disease affecting the esophagus, history 
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of radiation therapy or cryotherapy to the esophagus, or caustic or 
physiochemical trauma; current or historical evidence of Zollinger-
Ellison syndrome or other hypersecretory condition; history of gas-
tric, duodenal, or esophageal surgery except simple oversew of an 
ulcer; and acute upper gastrointestinal hemorrhage within 4 weeks 
prior to endoscopy.
This study was registered with ClinicalTrials.gov (NCT 
02351960; https://clinicaltrials.gov/ct2/show/NCT02351960), and 
was conducted in accordance with the protocol, the ethical prin-
ciples that have their origin in the Declaration of Helsinki, the ICH 
E6 GCP guidance, and all applicable regulations. Each subject (or 
the subject’s legally authorized representative) signed and dated the 
informed consent form before undergoing any study participation. 
The study was reviewed and approved by the Institutional Review 
Boards/Independent Ethics Committees of all study sites, consti-
tuted according to the applicable local requirements of each partici-
pating region. 
The names and numbers of the Institutional Review Boards are 
as follows:
•  Institutional Review Board of Taichung Veterans General 
Hospital (SC15048A)
•  Chang Gung Medical Foundation Institutional Review 
Board (104-0906A2)
•  Institutional Review Board of The Catholic University of 
Korea (KC14MSGV0846)
•  Asan Medical Center Institutional Review Board (2015-
0014)
•  Seoul National University Bundang Hospital Institutional 
Review Board (B-1412/277-008)
•  Seoul National University College of Medicine/Seoul Na-
tional University Hospital Institutional review board (H-
1411-076-626)
•  Yonsei University Health System, Severance Hospital, Insti-
tutional Review Board (4-2014-1023)
•  Samsung Medical Center Institutional Review Board 
(SMC-2014-11-079-001)
•  Institutional Review Board, National Cheng Kung Univer-
sity Hospital (AB-CR-104-004)
•  Joint CUHK-NTEC Clinical Research Ethics Committee 
(2014.681-T)
•  Kaohsiung Medical University Chung-Ho Memo-
rial Hospital Institutional Review Board (KMUHIRB-
F(I)-20150009)
•  Research Ethics Committee, National Taiwan University 
Hospital (201412003MSB)
Study Design
Based on the results of the screening endoscopy, the subjects 
were assigned to either the NERD study group or the EE study 
group, and were treated as follows (these regimens were already ap-
proved in the countries where this study was conducted):
 (1) NERD group: dexlansoprazole delayed-release 30 mg 
once-daily (QD) for 4 weeks
 (2) EE group: dexlansoprazole delayed-release 60 mg QD for 
8 weeks
During the study, dexlansoprazole delayed-release was self-ad-
ministered orally QD in the morning. Approximately 200 subjects 
were planned to be enrolled in the NERD study group and 100 
subjects in the EE study groups. Subjects from Taiwan were to be 
enrolled in the EE group only because dexlansoprazole 30 mg was 
not commercially available in the country.
Outcomes
During the study, efficacy was assessed via subject responses in 
a paper diary provided in local language (twice daily entries), inves-
tigator assessment of GERD symptoms (conducted at baseline and 
end of treatment, with an additional assessment at week 4 for sub-
jects in the EE group), and via endoscopy (conducted at screening 
and, for subjects in the EE group, repeated at end of treatment).
The primary endpoints were as follows:
 (1) The percentage of 24-hour heartburn and acid regurgita-
tion-free days over 4 weeks in NERD subjects following study 
drug treatment, as assessed by subject entries in a daily paper 
diary (completed twice a day)
 (2) The percentage of 24-hour heartburn and acid regurgi-
tation-free days over 8 weeks in EE subjects following study 
drug treatment, as assessed by subject entries in a daily paper 
diary (completed twice a day)
Other efficacy endpoints included the assessment of the indi-
vidual symptoms of heartburn and acid regurgitation separately, 
assessment for 24-hour and nighttime symptoms separately, investi-
gator assessment of GERD symptoms, assessment of subject-rated 
severity of nighttime symptoms, and (in the EE group) the percent-
age of study subjects with endoscopically evaluated macroscopic 
healing of their esophagus, with at least 1 LA grade classification 
grade improvement, at end of treatment.
Paper diary
Subjects documented the presence and maximum severity of 
daytime and nighttime heartburn and acid regurgitation symptoms 
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each day in the paper diary, which was to be completed every morn-
ing upon waking and every evening before bedtime. The grading 
of the severity of heartburn and acid regurgitation by the subjects is 
shown in Table 1.
Investigator assessment 
Clinicians (investigators) assessed the maximum severity of 
GERD symptoms (heartburn, acid regurgitation, dysphagia, belch-
ing, and epigastric pain) during the 7 days prior to the subject’s 
Table 1. Definitions of Heartburn and Acid Regurgitation Severity (Daytime/Nighttime) for Subject Daily Dairy
Severity (score 
assigned)
Definitions of daytime heartburn and acid regurgitation  
severity (daytime = awake time)
Definitions of nighttime heartburn and acid regurgitation  
severity (nighttime = sleep time)
None (0) No symptoms No symptoms
Mild (1) Occasional symptoms, can be ignored, does not influence daily 
routine
Occasional symptoms, can be ignored, does not influence sleep
Moderate (2) Symptoms cannot be ignored and/or occasionally influences 
daily routine
Symptoms cannot be ignored and/or occasionally influences 
sleep
Severe (3) Symptoms present most of day and/or regularly influences 
daily routine
Symptoms present most of night and/or regularly influences 
sleep
Very severe (4) Constant symptoms and/or markedly influences daily routine Constant symptoms and/or markedly influences sleep
Completed treatment (n = 197)
Prematurely discontinued (n = 11)
Pre-treatment event/AE (n = 6)
Voluntary withdrawal (n = 5)
Completed treatment (n = 76)
Prematurely discontinued (n = 12)
Pre-treatment event/AE (n = 3)
Significant protocol deviation (n = 5)
Voluntary withdrawal (n = 4)
Analysis
FAS (n = 207). One subject
excluded because of no post-
baseline efficacy data available.
SAF (n = 208)
Analysis
FAS (n = 88)
SAF (n = 88)
NERD group (n = 208)
Received intervention (n = 208)
Did not receive intervention (n = 0)
EE group (n = 88)
Received intervention (n = 88)
Did not receive intervention (n = 0)
Excluded (n = 149)
Not meeting eligibility criteria (n = 135)
Voluntary withdrawal (n = 14)
Endoscopy
Enrolled (n = 296)
Assessed for eligibility (N = 445)
Figure 1. Flow diagram illustrating 
patients enrolled in the study. NERD, 
non-erosive reflux disease; EE, erosive 
esophagitis; AE, adverse event; FAS, 
full analysis set; SAF, safety analysis set.
89
Phase 4 Dexlansoprazole GERD Study in Asia
Vol. 26, No. 1   January, 2020 (85-95)
study visit. The severity of each symptom was rated from 0 (none, 
ie, no symptom) to 4 (very severe, ie, symptom caused intense and 
constant discomfort and/or marked interference with usual activi-
ties, including sleep).
Statistical Methods
No formal sample size calculation was performed for this study; 
a total of approximately 300 subjects were considered sufficient to 
achieve the study endpoints.
The percentage of 24-hour heartburn and acid regurgitation-
free days were calculated for each subject with at least 1 daytime or 
nighttime heartburn and/or regurgitation result (yes or no) during 
treatment.
Summary statistics of percentage for the efficacy endpoints 
were generated for subjects in the full analysis set (all subjects who 
received at least 1 dose of study drug and had post-baseline data for 
Table 2. Key Demographic and Baseline Characteristics, Including Baseline Subject-rated Heartburn and Acid Regurgitation Scores (Safety 
Analysis Set)
Parameter
NERD subjects; dexlansoprazole  
30 mg (n = 208)
EE subjects; dexlansoprazole  
60 mg (n = 88)
Male gender (n [%]) 72 (34.6) 49 (55.7)
Age (mean [SD], yr) 53.6 (13.6) 51.7 (12.5)
Body weight (mean [SD], kg) 60.26 (11.62) 68.84 (14.99)
BMI (mean [SD], kg/m2) 23.00 (3.31) 25.11 (4.16)
12-Lead ECG (n [%])
    Within normal limits 141 (67.8) 55 (62.5)
    Abnormal but not clinically significant 67 (32.2) 33 (37.5)
    Abnormal and clinically significant 0 (0.0) 0 (0.0)








Number of days with heartburn or acid regurgitation (Days –8 to –2)
    Number of days with 24-hour heartburn or acid  
regurgitation
208 6.3 (1.2) 7.0 0-7 88 6.0 (1.6) 7.0 0-7
    Number of days with nighttime heartburn or  
acid regurgitation
208 5.0 (2.3) 6.0 0-7 88 5.3 (2.2) 6.5 0-7
    Number of days with daytime heartburn or  
acid regurgitation
208 5.6 (1.8) 6.0 0-7 88 5.2 (2.3) 7.0 0-7
Number of days with heartburn (Days –8 to –2)
    Number of days with 24-hour heartburn 208 5.6 (1.9) 7.0 0-7 88 5.3 (2.2) 6.0 0-7
    Number of days with nighttime heartburn 208 4.3 (2.6) 5.0 0-7 88 4.5 (2.6) 5.5 0-7
    Number of days with daytime heartburn 208 4.9 (2.3) 6.0 0-7 88 4.5 (2.6) 5.0 0-7
Number of days with acid regurgitation (Days –8 to –2)
    Number of days with 24-hour acid regurgitation 208 4.6 (2.5) 6.0 0-7 88 4.8 (2.6) 6.0 0-7
    Number of days with nighttime acid regurgitation 208 3.5 (2.8) 3.0 0-7 88 4.3 (2.8) 4.0 0-7
    Number of days with daytime acid regurgitation 208 3.9 (2.7) 4.0 0-7 88 4.2 (2.8) 5.0 0-7
Mean severity of heartburna
    Mean severity of 24-hour heartburn 208 1.11 (0.79) 0.93 0.0-4.0 88 1.12 (0.87) 0.93 0.0-3.8
    Mean severity of nighttime heartburn 208 1.07 (0.89) 0.86 0.0-4.0 88 1.13 (0.96) 1.00 0.0-4.0
    Mean severity of daytime heartburn 208 1.16 (0.81) 1.00 0.0-4.0 88 1.11 (0.90) 1.00 0.0-3.7
Mean severity of acid regurgitationa
    Mean severity of 24-hour acid regurgitation 208 0.89 (0.84) 0.71 0.0-4.0 88 1.10 (0.96) 0.89 0.0-3.8
    Mean severity of nighttime acid regurgitation 208 0.86 (0.90) 0.57 0.0-4.0 88 1.09 (0.98) 0.86 0.0-3.9
    Mean severity of daytime acid regurgitation 208 0.93 (0.87) 0.71 0.0-4.0 88 1.11 (1.01) 0.86 0.0-3.7
aScale for mean severity of heartburn and acid regurgitation: 1 = mild, 2 = moderate, 3 = severe, 4 = very severe.
BMI, body mass index; ECG, electrocardiogram; EE, erosive esophagitis; NERD, non-erosive reflux disease; SAF, safety analysis set.
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the appropriate efficacy variable) over 4 weeks in the NERD group 
and over 8 weeks in the EE group.
The safety analysis set included all subjects who received at 
least 1 dose of study drug. For subjects in the safety analysis set, the 
adverse event (AE) data and data on clinical laboratory tests, vital 
signs, physical examinations, and 12-lead electrocardiogram were 
summarized.
The Statistical Analysis System 9.2 or higher system for the 
UNIX operating system was used to perform the statistical analy-
ses. Statistical review of the study was performed by a biomedical 
statistician.
Results  
A total of 445 subjects were screened for the study: 208 subjects 
were enrolled into the NERD group and 88 subjects were enrolled 
into the EE group (Fig. 1).
Demographic and Baseline Characteristics
The key baseline and demographic characteristics, including 
baseline subject-rated heartburn and regurgitation scores are shown 
in Table 2.
The mean age of the subjects was 53.6 years in the NERD 
0
Percentage of days without 24-hour heartburn and acid regurgitation (4 wk)
Percentage of days without 24-hour heartburn (4 wk)
Percentage of days without 24-hour acid regurgitation (4 wk)
Percentage of days without nighttime heartburn and acid regurgitation (4 wk)
Percentage of days without nighttime heartburn (4 wk)
Percentage of days without nighttime acid regurgitation (4 wk)















Figure 2. Percentage (%) of days without heartburn and/or acid regurgitation in non-erosive reflux disease subjects; dexlansoprazole 30 mg (n = 
207). For each parameter, the percentage of days ranged from 0 to 100.
0
Percentage of days without 24-hour heartburn and acid regurgitation (8 wk)
Percentage of days without 24-hour heartburn (8 wk)
Percentage of days without 24-hour acid regurgitation (8 wk)
Percentage of days without nighttime heartburn and acid regurgitation (8 wk)
Percentage of days without nighttime heartburn (8 wk)
Percentage of days without nighttime acid regurgitation (8 wk)





















Percentage of days without nighttime heartburn and acid regurgitation (4 wk)
Percentage of days without nighttime heartburn (4 wk)
Percentage of days without nighttime acid regurgitation (4 wk)
Figure 3. Percentage (%) of days without heartburn and/or acid regurgitation in erosive esophagitis (EE) subjects; dexlansoprazole 60 mg (n = 
88). One subject in the EE group only took 1 day of study drug and provided no valid diary. For each parameter, the percentage of days ranged 
from 0 to 100.
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group and 51.7 years in the EE group. The mean body mass index 
was 23.00 kg/m2 in the NERD group and 25.11 kg/m2 in the EE 
group. In both the NERD and EE groups, for the 7 days prior 
to treatment with study drug, subjects experienced 24-hour heart-
burn or acid regurgitation for a median of 7 days. In both groups, 
daytime heartburn and acid regurgitation were more prevalent than 
nighttime heartburn and acid regurgitation.
Efficacy Results
The results of the subject-rated heartburn and acid regurgita-
tion assessments following treatment with dexlansoprazole are 
shown in Figures 2 and 3 (Table 3). The median percentage of 
days that subjects did not experience any 24-hour heartburn and 
acid regurgitation was 26.92% in the NERD group and 65.45% 
in the EE group. The median percentage of days that subjects did 
not experience any nighttime heartburn and acid regurgitation was 
59.26% in the NERD group and 83.33% in the EE group. For 
individual symptoms, the median percentage of days without night-
time heartburn was 73.08% and 92.73% respectively, and without 
nighttime acid regurgitation was 88.00% and 92.59% respectively, 
in the NERD and EE groups. The median severity (Table 3) of 
nighttime heartburn and of acid regurgitation ranged from 0.1 to 0.3 
in the 2 groups.
Regarding investigator assessment, in the NERD group, 
the percentage of subjects who experienced an at least 1-category 
improvement in the severity of the symptom was 69.7% for acid 
regurgitation, 66.7% for heartburn severity, 64.3% for belching, 
33.8% for epigastric pain, and 14.6% for dysphagia. Similarly, in 
the EE group, the percentage of subjects who experienced an at 
least 1-category improvement in the severity of the symptom was 
71.0% for acid regurgitation, 63.2% for heartburn severity, 42.1% 
for epigastric pain, 40.8% for belching, and 17.1% for dysphagia.
The detailed endoscopy results are shown in Table 4. Of the 
subjects in the EE group, 77.3% experienced at least a 1 LA grade 
improvement in EE from baseline to week 8, with 27 subjects 
(30.7%) having no EE at week 8.
Safety, Tolerability, and Compliance
The median exposure to treatment was 27 days in the NERD 
group and 56 days in the EE group. In the NERD group, 96.2% 
of subjects showed > 90.0% drug compliance, while in the EE 
Table 3. Subject-rated Nighttime Heartburn and Acid Regurgitation Severity Assessments in Subjects With Non-erosive Reflux Disease and 
Erosive Esophagitis (Safety Analysis Set)
Parameter














Severity of nighttime heartburn and acid regurgitationa
    Severity of nighttime heartburn 207 4 wk 0.63 (0.77) 0.31 0.0-4.0 87 8 wk 0.42 (0.69) 0.09 0.0-3.5
    Severity of nighttime acid regurgitation 207 4 wk 0.49 (0.71) 0.15 0.0-4.0 87 8 wk 0.38 (0.58) 0.09 0.0-2.7
    Severity of nighttime heartburn - - - - - 87 4 wk 0.46 (0.73) 0.11 0.0-4.0
    Severity of nighttime acid regurgitation - - - - - 87 4 wk 0.44 (0.62) 0.14 0.0-2.7
aScale for mean severity of heartburn and acid regurgitation: 1 = mild, 2 = moderate, 3 = severe, 4 = very severe.
EE, erosive esophagitis; FAS, full analysis set; NERD, non-erosive reflux disease.
One subject in the EE group only took 1 day of study drug and provided no valid diary.
Table 4. Number and Percentage of Subjects With Erosive Esopha-
gitis With Endoscopically Evaluated Macroscopic Healing (Safety 
Analysis Set) 
Endoscopy evaluation
Number of subjects (%)
EE subjects; dexlansoprazole 
60 mg (n = 88)
Baseline (n [%])
    No EE present 0 (0.0)
    Grade of EE
    Grade A 1 (1.1)
    Grade B 75 (85.2)
    Grade C 10 (11.4)
    Grade D 2 (2.3)
Week 8 (n [%])
    No EE present 27 (30.7)
    Grade of EE
    Grade A 36 (40.9)
    Grade B 12 (13.6)
    Grade C 1 (1.1)
    Grade D 0 (0.0)
    At least 1 LA grade improvement 
from baseline (n [%])
68 (77.3)
EE, erosive esophagitis; LA, Los Angeles.
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group, 94.3% of subjects showed > 90.0% drug compliance.
Table 5 shows the frequency of AEs in the 2 groups. In the 
NERD group, 16.8% of subjects reported treatment-emergent 
AEs (TEAEs), with a small proportion of subjects (6.7%) experi-
encing TEAEs related to the study drug. In the EE group, 35.2% 
of subjects reported TEAEs, with 5.7% experiencing TEAEs 
related to the study drug. Most TEAEs were mild in intensity in 
both groups. No TEAEs were reported in ≥ 5.0% of subjects in 
either group. TEAEs that occurred in 2.0% or more subjects were 
headache in the NERD group (2.4%) and diarrhea in the EE 
group (2.3%).
TEAEs that led to study drug discontinuation were reported 
by 6 subjects in the NERD group and 3 subjects in the EE group. 
In the NERD group, there were no reports of serious AEs or 
deaths. In the EE group, 1 subject experienced a serious AE of 
mild urticaria on day 1, which was considered related to study drug; 
in addition, 1 subject experienced a treatment-emergent serious AE 
(SAE) leading to death. The death occurred in a 68-year-old male 
subject who experienced metastatic adenocarcinoma, diagnosed 
on omental nodule biopsy. The SAE start date was on day 66 (10 
days after the last study treatment), and it lasted for 106 days. The 
patient also had comorbid hypertension, diabetes mellitus, and hy-
perlipidemia. The outcome of the metastatic adenocarcinoma was 
fatal and was considered not related to the study drug.
No clinically important findings were noted in the clinical labo-
ratory, vital sign, or physical examination data.
Discussion  
GERD is a common condition with an increasing prevalence in 
Asia. GERD symptoms can be troublesome and are associated with 
impaired daily living, poorer quality of life, decreased work pro-
ductivity, and increased costs. A substantial proportion of patients 
continue to experience troublesome GERD symptoms despite 
treatment with the current PPIs. Dexlansoprazole delayed-release is 
a recently developed PPI with the novel dual delayed-release tech-
nology for extended duration of acid suppression. In Asian patients 
who require treatment for GERD, the effectiveness of the use of 
dexlansoprazole delayed-release has not been sufficiently character-
ized at the dose regimens of 30 mg/day for NERD and 60 mg/day 
for EE.
In this large multicenter study conducted in 3 Asian countries, 
in subjects with NERD, dexlansoprazole delayed-release 30 mg 
QD for 4 weeks relieved both daytime and nighttime heartburn and 
acid regurgitation. Symptom improvement was observed on both 
subject self-report and investigator ratings of GERD symptoms. 
For all the outcomes (except percentage of days without 24-hour 
heartburn and acid regurgitation), most patients reported relief for 
at least 50.0% of the days in the study. This finding should be un-
derstood in the context of the baseline status of the patients, during 
which the vast majority of the patients reported near-daily 24-hour 
heartburn or acid regurgitation symptoms (mean 6.3 days and me-
dian 7 days of heartburn or acid regurgitation in the 7 days prior to 
treatment). In subjects with EE, whose baseline GERD symptom 
Table 5. Frequency of Adverse Events in the Non-erosive Reflux Disease and Erosive Esophagitis Groups (Safety Analysis Set) 
Parameter
Number of events or number of subjects (%)
NERD subjects; dexlansoprazole  
30 mg (n = 208)
EE subjects; dexlansoprazole  
60 mg (n = 88)
Events Subjects Events Subjects
TEAEs 53 35 (16.8) 59 31 (35.2)
    Related 22 14 (6.7) 5 5 (5.7)
    Not related 31 23 (11.1) 54 26 (29.5)
    Mild 36 26 (12.5) 41 29 (33.0)
    Moderate 13 11 (5.3) 15 7 (8.0)
    Severe 4 2 (1.0) 3 3 (3.4)
    Leading to study drug discontinuation 10 6 (2.9) 3 3 (3.4)
Serious TEAEs 0 0 (0.0) 2 2 (2.3)
    Related 0 0 (0.0) 1 1 (1.1)
    Not related 0 0 (0.0) 1 1 (1.1)
    Leading to study drug discontinuation 0 0 (0.0) 1 1 (1.1)
Deaths 0 (0.0) 1 (1.1)
NERD, non-erosive reflux disease; EE, erosive esophagitis; TEAE, treatment-emergent adverse event.
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frequency was broadly comparable to that of subjects with NERD, 
dexlansoprazole delayed-release 60 mg QD for 8 weeks relieved 
both daytime and nighttime heartburn and acid regurgitation on 
self- and investigator-ratings; most patients reported relief for at 
least 50.0% of the days on all outcomes. Three in 4 patients in this 
group experienced at least 1 LA grade improvement in esophagitis, 
with approximately one-third of the patients showing no evidence of 
EE at the end of treatment. The mean severity of nighttime heart-
burn and nighttime regurgitation was also numerically lower at end 
of treatment than baseline status in both groups. An improvement 
in the frequency and severity of these symptoms can be expected to 
translate to better quality of life and productivity.17
The EE healing rate in this study (30.7%) was lower than that 
seen in the dexlansoprazole pivotal trials in which the EE healing 
rate was higher than 80.0% after 8 weeks of treatment with dexlan-
soprazole.18 These pivotal trials were conducted mainly in North 
American and European centers. A review of studies with PPIs 
showed that EE healing rates were significantly lower in non-white 
patients than in white patients.19 A similar difference between Asian 
and non-Asian patients was reported in a pragmatic trial with pan-
toprazole for GERD.20 Low EE healing rates were also reported in 
a Chinese study, in which 75.8% of patients experienced complete 
symptom resolution but only 48.0% showed complete healing of 
esophagitis after 8 weeks of treatment with esomeprazole 20 mg.21
Treatment with dexlansoprazole delayed-release 30 mg/day in 
subjects with NERD for 4 weeks and 60 mg/day in subjects with 
EE for 8 weeks was well tolerated. AEs related to the study drug 
were uncommon (6.7% in the NERD group and 5.7% in the EE 
group), and AEs resulting in study drug discontinuation were 
reported in fewer than 4.0% of the subjects in each group. In the 
NERD group, over 4 weeks, no SAEs or deaths were reported. In 
the EE group, 1 SAE leading to death was reported and it was not 
considered related to dexlansoprazole.
In subjects with EE, the data suggested that further improve-
ments in efficacy with treatment occurred during the period from 4 
weeks to 8 weeks. As an example, the median severity of nighttime 
acid regurgitation was 0.14 at 4 weeks and 0.09 at 8 weeks. Similar 
numerical differences between week 4 and week 8 were seen for the 
other nighttime symptom parameters in subjects with EE. It is pos-
sible that subjects with NERD may also have continued to show 
further improvement with a longer treatment period extending to 8 
weeks or longer.
A comparison of outcomes between patients with NERD and 
EE shows that, at 4 weeks, the efficacy was consistently higher in 
EE patients than in NERD patients. While no statistical compari-
sons were conducted, efficacy was numerically higher in EE for 
both daytime and nighttime symptoms, and for both heartburn and 
regurgitation symptoms; differences between EE and NERD were 
less pronounced for regurgitation symptoms. As an example, after 
4 weeks of treatment, the mean percentage of days that subjects did 
not experience any nighttime heartburn was 70.0% in the EE group 
compared with 59.6% in the NERD group; for regurgitation 
symptoms, the respective percentages were 69.2% in the EE group 
and 67.4% in the NERD group. As noted earlier, GERD severity 
in both groups was broadly similar at baseline. While the dose of 
dexlansoprazole was lower in NERD patients than in EE patients, 
this is unlikely to explain the observed difference in outcomes; 
in NERD, the 30 mg and 60 mg doses of dexlansoprazole have 
showed comparable efficacy.15 This differential efficacy between EE 
and NERD appears to be related to the disease process itself, and 
is in keeping with the reported literature in which efficacy rates are 
consistently higher in EE than in NERD.22,23
The demonstration of improvement in both daytime and 
nighttime symptoms with a single daily dose of dexlansoprazole is 
encouraging. In a large recent survey (the GERD in Asia Pacific 
Survey), 45.0% of patients reported limited improvement in noc-
turnal symptoms despite regular treatment with PPIs.24 Therefore, 
dexlansoprazole, which has shown high response rates, 24-hour pH 
control, and reduction in nocturnal symptoms with once-daily dos-
ing in this study, can be expected to meet an important medical need 
in Asian patients.25
A key limitation of this study was the absence of a compara-
tor arm. No formal sample size calculation was performed for this 
study, and all patients received treatment with dexlansoprazole. 
Therefore, efficacy and safety of dexlansoprazole in comparison 
with placebo or an active comparator could not be established in this 
study. However, the overall efficacy and safety of dexlansoprazole 
delayed-release have been established in previous studies, and this 
treatment is already approved in Hong Kong, South Korea, and 
Taiwan. Therefore, an open-label uncontrolled study was sufficient 
to characterize the use of dexlansoprazole in the studied doses. 
Notably, the efficacy of dexlansoprazole was demonstrated not 
only on subjective assessments but also on endoscopic evaluations 
in subjects with EE. Another limitation of this study was that the 
statistical analyses were generally restricted to summary statistics; 
therefore, a detailed assessment of the factors associated with effi-
cacy could not be conducted.
Future studies should focus on a longer duration of treatment 
with more frequent assessments to understand the trajectory of 
improvement with dexlansoprazole; studies should also attempt to 
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identify those subgroups that are most likely to benefit with treat-
ment with this drug.
In summary, in Asian patients with GERD, treatment with 
dexlansoprazole delayed-release 30 mg/day for 4 weeks in subjects 
with NERD and 60 mg/day for 8 weeks in subjects with EE indi-
cated a favorable efficacy and safety profile in relieving both daytime 
and nighttime heartburn and acid regurgitation symptoms.
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